title: Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
abstract: BACKGROUND
  Oral anticoagulation therapy with vitamin K antagonists (VKA) such as warfarin and acenocoumarol is recommended in patients with atrial fibrillation (AF) and risk factors for embolism. The quality of anticoagulation control with VKA may be assessed by the time in therapeutic range (TTR). In our country, there are no data available about the quality of anticoagulation in patients with AF. The primary goal of our study was to assess the level of effective anticoagulation in a multicenter network of anticoagulation clinics in Argentina, which included patients with nonvalvular AF (NVAF) treated with VKA oral anticoagulants.
  
  
  METHODS
  The TERRA trial is a multicenter, cross-sectional study involving 14 anticoagulation clinics that were invited to participate and recruit 100 consecutive patients with NVAF treated with VKA for more than 1 year. The international normalized ratio (INR) values were retrospectively obtained from patient charts, and TTR was calculated using the Rosendaal method.
  
  
  RESULTS
  A total of 1190 patients were included in the analysis. Mean age was 74.9 ± 9.9 years, and 52.5% of the patients were male. Median TTR was 67.5% (interquartile interval 54-80). During 55% of the TTR, INR was >3. Interinstitution variability was substantial, with a range of 57.7% ± 17% to 87.7% ± 17%, P < .001. The 10th percentile of TTR was 41%, the 20th percentile was 50%, the 30th was 58%, and the 35th percentile was 60%. In 40% of patients, TTR was <70%.
  
  
  CONCLUSIONS
  In this multicenter study, mean TTR values in patients with AF under VKA were similar to those in international therapeutic clinical trials (55%-65%). Marked variations among institutions were observed and, although average results obtained were high, one third of the patients exhibited a TTR below 60%. This cutoff value is conservative according to current recommendations, and guidelines suggest that when management with VKA cannot be improved, patients should be switched to direct oral anticoagulants. The addition of TTR calculation to clinical practice may help improve the quality of oral anticoagulation in patients with AF, thus improving anticoagulation outcomes.
authors.affiliation: 1 Cardiology Deparment, Hospital El Cruce, Florencio Varela, Argentina.
authors.forename: Carlos
authors.initials: C
authors.lastname: Tajer
authors.affiliation: 2 Hematology Deparment, Hospital Británico, Buenos Aires, Argentina.
authors.forename: José
authors.initials: J
authors.lastname: Ceresetto
authors.affiliation: 3 Clinical Medicine Department, Hospital Británico, Buenos Aires, Argentina.
authors.forename: Federico Jorge
authors.initials: FJ
authors.lastname: Bottaro
authors.affiliation: 4 Hematology Department, Hospital El Cruce, Florencio Varela, Argentina.
authors.forename: Alejandra
authors.initials: A
authors.lastname: Martí
authors.affiliation: 5 Hematology Department, FLENI, Buenos Aires, Argentina.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Casey
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001118:Argentina; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D011786:Quality Control; D012042:Registries; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D000925:Anticoagulants; D014812:Vitamin K
keywords: anticoagulants; atrial fibrillation; time in therapeutic range